Related Experiment Video
Updated: Jul 16, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Characterizing the Mutational Landscape of In-Transit Melanoma Metastases
Luisa Quesada Camacho1, Mohamad El Moheb2,3, Mackenzie M Mayhew2
1Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Abstract:
In-transit melanoma (ITM) is a unique presentation of metastatic cutaneous melanoma associated with therapeutic challenges. Despite its clinical importance, the molecular drivers of ITM remain poorly defined. We aimed to characterize the mutational landscape of ITM and identify genetic alterations distinguishing it from other melanoma metastases. Tumor samples from 528 patients in the MSK-IMPACT dataset, comprised of over 300 cancer-related genes, were analyzed. Samples were classified as primary, in-transit, regional lymph node, or distant metastases. Driver mutation frequencies were compared across groups, and mutual information (MI) and principal component analysis (PCA) were used to identify ITM-associated genes and mutation patterns. NRAS Q61 mutations were enriched in ITM compared with other melanoma sites, while NF1 mutations were less common. Exploratory MI, PCA, and pairwise analyses identified recurrent NRASMUT/wild-type gene patterns that may distinguish ITM from other melanoma samples. Genes retained in the wild-type state alongside NRASMUT were associated with PI3K/AKT/mTOR, TGF-β, and E2F-related pathways. Collectively, these findings suggest that ITM is enriched for NRAS Q61 mutations and may have a comparatively lower co-mutation burden, providing a basis for future studies of ITM biology and clinical behavior.
Insights
In-transit melanoma (ITM) shows a distinct mutational profile, enriched for NRAS Q61 mutations. This finding may explain ITM
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- In-transit melanoma (ITM) presents unique therapeutic challenges.
- The molecular drivers of ITM are not well understood.
Purpose of the Study:
- Characterize the mutational landscape of ITM.
- Identify genetic alterations distinguishing ITM from other melanoma metastases.
Main Methods:
- Analyzed tumor samples from 528 patients using the MSK-IMPACT dataset (over 300 cancer-related genes).
- Classified samples into primary, in-transit, regional lymph node, or distant metastases.
- Compared driver mutation frequencies and used mutual information (MI) and principal component analysis (PCA) for pattern identification.
Main Results:
- NRAS Q61 mutations were significantly enriched in ITM compared to other melanoma sites.
- NF1 mutations were less frequent in ITM.
- Identified NRAS-mutant/wild-type gene patterns potentially distinguishing ITM, with associated PI3K/AKT/mTOR, TGF-β, and E2F pathways.
Conclusions:
- ITM exhibits a distinct molecular profile enriched for NRAS Q61 mutations.
- ITM may have a lower co-mutation burden compared to other metastatic sites.
- Findings provide a foundation for further research into ITM biology and clinical behavior.

